GlassScriptPhysician profile
Navin Kumar Kesari
NPI 1467879940
$10,541.80
in general payments reported to CMS, 2019-2025
64 companies · $3,140 in 2025
The $3,140 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $84.50 · 2021: $491 · 2022: $1,152 · 2023: $1,916 · 2024: $2,875 · 2025: $3,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,819 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,819.22 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,035.86 | 2021-2025 | |
| Argenx US, INC. | $699.47 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Abbott Laboratories | $620.04 | 2021-2025 | Infinity, Proclaim, Eterna |
| Teva Pharmaceuticals USA, INC. | $571.88 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $540.63 | 2021-2025 | |
| Amgen INC. | $462.13 | 2022-2025 | Uplizna, Aimovig |
| Ucb, INC. | $454.50 | 2019-2025 | Rystiggo, Fintepla |
| Takeda Pharmaceuticals U.S.A., INC. | $439.90 | 2023-2025 | Hyqvia |
| Acorda Therapeutics, INC | $348.86 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $343.32 | 2022-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $334.31 | 2023-2025 | Ultomiris |
| Lundbeck LLC | $326.19 | 2021-2025 | Rexulti, Vyepti |
| Grifols USA, LLC | $318.96 | 2019-2025 | Gamunex-C, Xembify |
| Genentech USA, INC. | $317.14 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
| Horizon Therapeutics Plc | $225.18 | 2021-2023 | Uplizna |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Kesari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.